Camurus AB operates as a research based pharmaceutical company. The company is headquartered in Lund, Skane and currently employs 285 full-time employees. The company went IPO on 2015-12-03. The firm has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
最新の財務諸表(Form-10K)によると、Camurus AB (publ)の総資産は$4,739で、純利益は$735です。
CAMRFの主要な財務比率は何ですか?
Camurus AB (publ)の流動比率は9.4、純利益率は32.45、1株当たり売上高は$38.23です。
Camurus AB (publ)の収益はセグメントまたは地域別にどのように分けられていますか?
Camurus AB (publ) の最大収益セグメントは Sales of Development Related Goods and Services で、最新の利益発表における収益は 2,252,000 です。地域別に見ると、Sweden が Camurus AB (publ) の主要市場であり、収益は 117,170,000 です。